Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient

Navaneeth Narayanan, Christopher D. Adams, David W. Kubiak, Serena Cheng, Robyn Stoianovici, Leonid Kagan, Luigi Brunetti

Research output: Contribution to journalArticle

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment ofMRSA infections.Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.

Original languageEnglish (US)
Pages (from-to)877-891
Number of pages15
JournalInfection and Drug Resistance
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Infection
Pharmacokinetics
Obesity
Anti-Bacterial Agents
Therapeutics
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Keywords

  • Antibiotics
  • Methicillin-resistant staphylococcus aureus
  • Obesity
  • Pharmacokinetics

Cite this

Narayanan, Navaneeth ; Adams, Christopher D. ; Kubiak, David W. ; Cheng, Serena ; Stoianovici, Robyn ; Kagan, Leonid ; Brunetti, Luigi. / Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient. In: Infection and Drug Resistance. 2019 ; Vol. 12. pp. 877-891.
@article{6812a79c27b14cb08ecac1de531bee07,
title = "Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient",
abstract = "Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment ofMRSA infections.Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.",
keywords = "Antibiotics, Methicillin-resistant staphylococcus aureus, Obesity, Pharmacokinetics",
author = "Navaneeth Narayanan and Adams, {Christopher D.} and Kubiak, {David W.} and Serena Cheng and Robyn Stoianovici and Leonid Kagan and Luigi Brunetti",
year = "2019",
month = "1",
day = "1",
doi = "https://doi.org/10.2147/IDR.S196264",
language = "English (US)",
volume = "12",
pages = "877--891",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",

}

Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient. / Narayanan, Navaneeth; Adams, Christopher D.; Kubiak, David W.; Cheng, Serena; Stoianovici, Robyn; Kagan, Leonid; Brunetti, Luigi.

In: Infection and Drug Resistance, Vol. 12, 01.01.2019, p. 877-891.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of treatment options for methicillin-resistant Staphylococcus aureus infections in the obese patient

AU - Narayanan, Navaneeth

AU - Adams, Christopher D.

AU - Kubiak, David W.

AU - Cheng, Serena

AU - Stoianovici, Robyn

AU - Kagan, Leonid

AU - Brunetti, Luigi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment ofMRSA infections.Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.

AB - Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a major cause of infection in both the hospital and community setting. Obesity is a risk factor for infection, and the prevalence of this disease has reached epidemic proportions worldwide. Treatment of infections in this special population is a challenge given the lack of data on the optimal antibiotic choice and dosing strategies, particularly for treatment ofMRSA infections.Obesity is associated with various physiological changes that may lead to altered pharmacokinetic parameters. These changes include altered drug biodistribution, elimination, and absorption. This review provides clinicians with a summary of the literature pertaining to the pharmacokinetic and pharmacodynamic considerations when selecting antibiotic therapy for the treatment of MRSA infections in obese patients.

KW - Antibiotics

KW - Methicillin-resistant staphylococcus aureus

KW - Obesity

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85067571244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067571244&partnerID=8YFLogxK

U2 - https://doi.org/10.2147/IDR.S196264

DO - https://doi.org/10.2147/IDR.S196264

M3 - Article

VL - 12

SP - 877

EP - 891

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

ER -